Matt De Silva is the founder and chairman of Notable Labs, a clinical-stage precision therapeutics company developing predictive ex vivo technology to identify, from a blood sample taken before treatment, whether a patient will positively respond to a given treatment. He is also currently a Venture Partner at Builders VC, a Series A and seed-focused venture firm based in San Francisco. De Silva focuses on the healthcare and life science investment practice.

Prior to Notable, which he ran as CEO from 2014 to 2020, he was a macro hedge fund portfolio manager at Peter Thiel’s family office Thiel Capital. Prior to Thiel Capital, De Silva was an analyst at Bank of America Merrill Lynch. He graduated from Cornell University in Applied Economics and Management and was the captain of the cross country team.

• 

  Venture Partner - Health in Builders VC

  We help founders modernize antiquated industries

• 

  Chief Operating Officer (COO) in Pathos

  The AI-Driven Biotechnology Company